
Context Therapeutics Investor Relations Material
Latest events

Q1 2025
9 Jul, 2025

Q4 2024
19 Mar, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Context Therapeutics Inc
Access all reports
Context Therapeutics Inc. is a clinical-stage biopharmaceutical company that focuses on developing therapies for solid tumors. The company's primary focus is on T cell-engaging bispecific antibodies, including its lead candidate, CTIM-76. This investigational therapy targets Claudin 6 (CLDN6), a protein expressed in various solid tumors such as ovarian, endometrial, and testicular cancers, while being minimally present in healthy tissues. Another key candidate in their pipeline is CT-95, a bispecific antibody targeting mesothelin, which is also aimed at treating solid tumors. Context Therapeutics is headquartered in Philadelphia, Pennsylvania, and its shares are listed on the NASDAQ.
Latest articles
)
Eli Lilly: The Pharma Giant Behind Mounjaro and Zepbound
Eli Lilly's journey from insulin pioneer to global pharma giant, leading innovation in diabetes, obesity, and the future of metabolic health.
30 Jun 2025
)
500 Years of Craft, One Family Legacy: Beretta Holding's Global Expansion
How Beretta Holding managed to transform from a 16th-century gun barrel producer into a global industrial group while preserving 500 years of legacy.
27 Jun 2025
)
Shuntaro Furukawa: The Sixth President of Nintendo
Shuntaro Furukawa, Nintendo's sixth president, went from a childhood fan to leading the company through global expansion and the launch of Switch 2.
23 Jun 2025
Ticker symbol
CNTX
Country
🇺🇸 United States